DENTAL-MONITORING
16.3.2020 19:13:09 CET | Business Wire | Press release
Dental Monitoring tele dentistry solutions allow dental professionals to connect with their patients remotely and in a HIPAA compliant manner. Our unique technology enables dentists and orthodontists to assess, monitor treatment, and communicate with their patients as much as needed, even when they are at home.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200316005750/en/
Given the unprecedented situation we are facing worldwide, and with patient access to practices becoming more difficult, Dental Monitoring’s priorities have shifted to supporting all dental professionals whoever and wherever they are, to continue the care of their patients, as well as ensuring the continuity of their practices. Our current solutions use the full extent of our AI engine, and complete onboarding for practices can often take a few weeks to integrate fully. Therefore we have decided to refocus our company priorities to launch immediately two new “Light ” versions of our existing solutions. These new versions will be simpler and more immediate to implement for these times - rapid on-boarding and roll-out to all patients:
Photo Monitoring Light :
Simplified at-home monitoring platform with instant two-way communication with patients.
Capturing pictures of the mouth through the DM App allowing doctors to :
- Evaluate remotely their patients' current oral situation or treatment progress as if they were in the practice
- Have two way communication and guidance between doctor and patient
- Send annotated pictures directly via the patient App so patients can better understand their doctor’s guidance.
Photo Monitoring Light will also enable the clinical team to request an immediate DM scan when a patient requests immediate feedback, so that the doctor can better evaluate the patient’s situation and advise accordingly.
To implement Photo Monitoring Light: please visit https://dental-monitoring.com/maintain-patient-care/
SmileMate Virtual Consultation:
Remote assessment of new and existing patients.
All patient calls can be pre-qualified remotely using the SmileMate assessment tool directly through doctors practice websites.
The process is simple:
Step 1- The patient clicks on the widget on the doctor’s website, creates a profile and takes five intra-oral pictures on their smartphone (no need to download an app or use cheek retractors)
Step 2- A comprehensive customized report and treatment option is automatically generated by our AI engine and sent to the doctor
Step 3- Doctors qualify the patient’s needs on their SmileMate portal
Step 4- Doctors customize and share the report with the patient with advice or a booking link.
To implement SmileMate Virtual Consultation please visit: https://dental-monitoring.com/maintain-patient-care/
Fast-Track Accelerated On-Boarding.
Photo Monitoring Light and SmileMate Virtual Consultation are ready for use in minutes after doctors and their teams have performed our free fast-track accelerated training. Implementing fast-track onboarding into dental practices is simplified through our new streamlined process, which is done 100% remotely through webinars by our customer support team.
Call us or visit: https://dental-monitoring.com/maintain-patient-care/
to book a time slot for our next training session.
Opening up a dedicated 24/7 hotline to answer any questions or needs during the pandemic.
Our priority has always been our customers and their patients. Over the next few months, we will be solely focused on delivering solutions that can help doctors maintain the expert care they provide to their patients. To that extent, and during the pandemic, we will maximize accessibility to our solutions by reducing our price on these new solutions by 50% :
- Photo Monitoring Light will be accessible for US$3 per month/patient monitored
- For SmileMate Virtual Consultation will be at US$150/month for 50 unique patient scans
We have also directed our worldwide sales force to focus 100% on Customer Service - working side by side with doctors to help treat their patients remotely.
About Dental Monitoring
(www.dental-monitoring.com
)
Founded in 2015 by Philippe Salah, Dental Monitoring is the first AI-based company to target dental professionals’ needs. The DM software suite is designed to address the needs of dental professionals all along the patient journey: before treatment to increase the patient’s engagement, during treatment to improve the quality of care provided by the doctor, and after treatment to ensure the stability of the treatment outcome. The company currently operates in Europe, the United States, and Asia-Pacific. It employs a team of about 250 employees across its 5 offices located in Paris, Austin, London, Hong Kong, and Sydney.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200316005750/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 14:00:00 CEST | Press release
New Q1 2026 “Agentic Commerce Pulse” survey from Riskified reveals a growing trust gap in agent-driven commerce, as consumers embrace AI across the shopping journey but remain hesitant to hand over control amid concerns over fraud, security, and accountability Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-maki
Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 14:00:00 CEST | Press release
90% of dealmakers expect cross-border M&A activity to increase over the next 12–24 months75% cite foreign direct investment screening as the biggest threat to deal completion88% report longer signing-to-close timelines than three years ago Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environ
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 13:43:00 CEST | Press release
For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs) Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing a
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 13:00:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415938477/en/ Photo credit: Jos Schmid, Photographer
tesa Selects Kinaxis as the Digital Backbone for Global Integrated Business Planning Transformation27.4.2026 13:00:00 CEST | Press release
Kinaxis Maestro™ platform to serve as the foundation for a multi‑year transformation to resilient, globally orchestrated planning ecosystem Kinaxis® (TSX: KXS), a global leader in end‑to‑end supply chain orchestration, today announced that tesa SE, a global manufacturer of adhesive tapes and self-adhesive product solutions, has selected the Kinaxis Maestro™ platform as a core enabler of its global, multi‑year supply chain and integrated business planning (IBP) transformation. Following an extensive evaluation, tesa selected Kinaxis to support its evolution from regionally fragmented planning practices toward a centrally governed, globally orchestrated IBP operatingmodel. Kinaxis will support tesa in improving enterprise-wide transparency, strengthening resilience, and enabling faster, more informed decision making across an increasingly complex and volatile global supply chain network. With 130 years of innovation, tesa is one of the world’s leading manufacturers of adhesive tapes and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom